Neomatrix develops personalized DNA vaccines that target tumor neoantigens to eliminate cancer cells while enhancing immune response through a potent delivery system. This approach addresses the challenge of effectively treating various cancers, including melanoma and lung cancer, by enabling health professionals to monitor early symptoms and tailor therapies to individual patients.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatments often lack specificity, leading to systemic toxicity and limited efficacy, particularly in heterogeneous tumors. Monitoring early symptoms and tailoring therapies to individual patients remains a significant challenge.
Solution
Neomatrix develops fully-synthetic, personalized DNA vaccines designed to selectively eliminate tumor cells while enhancing the patient's immune response. Their approach leverages a deep understanding of cancer biology and immuno-oncology, combined with cutting-edge technologies to identify patient-specific tumor neoantigens. The personalized vaccines are delivered via a potent delivery system to maximize the immune response and create a synergistic effect with immune checkpoint inhibitors. This enables health professionals to tailor therapies to individual patients.
Target Audience
The primary target audience includes specialty oncology centers and key opinion leaders (KOLs) focused on personalized cancer immunotherapy.
Features
- Identification of patient-specific tumor neoantigens using advanced genomic analysis.
- Design and production of fully-synthetic, personalized DNA vaccines.
- Potent delivery system to maximize immune response.
- Synergistic effect with immune checkpoint inhibitors.
- Biomarker assay under advanced development.